Cipla is trading at Rs 1439.05, reflecting a 2.73% decrease today, while the one-week returns are at 1.6%. Cipla is currently priced at Rs 1434.00, indicating a 3.07% drop for today. The five-day ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be ...

At the awards night, Cipla took home a total of 4 metals across categories for its impressive work and creativity. The brand won 2 silver and 2 bronze metals across categories. Apart from Cipla ...

The FDA’s decision is based on a comprehensive data package and the totality of evidence, including the results from a phase III study demonstrating biosimilarity between AVTOZMA and reference ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Cipla's shares are currently priced at Rs 1439.65, reflecting a modest rise of 0.82%. The 7-day simple moving average is Rs 1475.93. Cipla is currently valued at Rs 1437.65, with a daily increase of 0 ...

Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection at the manufacturing facility of Medispray Laboratories Private Limited, a wholly ...

Cipla said the United States Food and Drug Administration (USFDA) conducted an inspection at the manufacturing facility of its subsidiary, Medispray Laboratories, in Goa, from 14 to 20 January 2025.